GlobeNewswire Inc | Sep 23, 2021 06:30AM EDT

September 23, 2021

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (Annexon) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain and eye, today announced that Douglas Love, Esq., President & Chief Executive Officer, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 12:40 p.m. ET.

A live webcast of the event can be accessed under the Events & Presentations section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain and eye. The companys pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visitwww.annexonbio.com.

Contacts:

Investors:Jennifer LewChief Financial Officer, Annexon Biosciences jlew@annexonbio.com

Media:Miriam Mason Annexon Biosciences mmason@annexonbio.com